FALCO HOLDINGS Co., Ltd. Financial Summary for the Second Quarter (Interim) of the Fiscal Year Ending March 2027 [Japanese GAAP] (Consolidated)

Summary of Results

During the interim period, increased sales and profits in the clinical testing and ICT businesses resulted in net sales of 22,148 million yen, operating income of 1,490 million yen, ordinary income of 1,586 million yen, and net income attributable to owners of parent of 957 million yen. In clinical testing, stronger sales activities and improved productivity contributed, while in ICT the expansion in the number of cloud-based service deployments contributed. Progress was also made on regulatory approvals and consideration for insurance coverage related to genomics. The full-year forecast for the current fiscal year remains unchanged from the previous announcement. There are no major revisions to the dividend forecast.

Outlook and Capital Allocation

The solid interim performance was driven by growth in clinical testing and ICT, which are the Company’s growth drivers. Under the long-term vision FALCO VISION 2030 and the mid-term plan FALCO INNOVATION 2026, the Company will continue to strengthen both its foundation and growth areas. There is no change to the most recently disclosed dividend forecast, and no additional information on treasury stock acquisitions is provided at this time.